By a News Reporter-Staff News Editor at Clinical Oncology Week -- Investigators publish new report on Adenocarcinomas. According to news originating from Tehran, Iran, by NewsRx correspondents, research stated, "In recent years, molecular imaging by magnetic resonance imaging (MRI) has gained prominence in the detection of tumor cells. The scope of this study is on molecular imaging and on the cellular uptake study of a glycosylated silica nanoprobe (GSN)."
Our news journalists obtained a quote from the research from Islamic Azad University, "In this study, intracellular uptake (HT 29 cell line) of GSN was analyzed quantitatively and qualitatively with inductively coupled plasma atomic emission spectroscopy, flow cytometry, and fluorescent microscopy. In vitro and in vivo relaxometry of this nanoparticle was determined using a 3 Tesla MRI; biodistribution of GSN and Magnevist ® were measured in different tissues. Results suggest that the cellular uptake of GSN was about 70%. The r(1) relaxivity of this nanoparticle in the cells was measured to be 12.9 +/- 1.6 mM(-1) s(-1) and on a per lanthanide gadolinium (Gd3+) basis. Results also indicate an average cellular uptake of 0.7 +/- 0.009 pg Gd3+ per cell. It should be noted that 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay demonstrated that the cells were effectively labeled without cytotoxicity, and that using MRI for quantitative estimation of delivery and uptake of targeted contrast agents and early detection of human colon cancer cells using targeted contrast agents, is feasible."
According to the news editors, the research concluded: "These results showed that GSN provided a critical guideline in selecting these nanoparticles as an appropriate contrast agent for nanomedicine applications."
For more information on this research see: Cellular uptake and imaging studies of glycosylated silica nanoprobe (GSN) in human colon adenocarcinoma (HT 29 cell line). International Journal of Nanomedicine, 2013;8():3209-3216. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Adenocarcinomas).
The news correspondents report that additional information may be obtained from B. Mehravi, Islamic Azad Univ, Dept. of Biol Sci, Sch Sci, Sci & Res Branch, Tehran, Iran. Additional authors for this research include M. Ahmadi, M. Amanlou, A. Mostaar, M.S. Ardestani and N. Ghalandarlaki.
Keywords for this news article include: Iran, Asia, Tehran, Oncology, Colon Cancer, Nanotechnology, Adenocarcinomas, Gastroenterology, Molecular Imaging, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC